Key Highlights

  • Shares traded at A$0.012 during the 5 November 2026 session, down 7.69%.
  • The entitlement offer raised approximately A$912,962 before costs.
  • Firm commitments were received for a Placement of about 55 million shares at A$0.01, raising about A$550,000.

Shares in Cynata Therapeutics Limited (ASX:CYP) traded at A$0.012 during the Trading session on 5 November 2026, down 7.69% in the early afternoon. The S&P/ASX 200 was up 1.87%, trading near 9,000 points. Cynata is a Melbourne-based regenerative medicine company developing cell therapy programs. Its latest announcement, dated 4 November 2026, confirms the completion of an entitlement offer and a further placement.

Entitlement offer completed and placement secured, 4 November 2026

Cynata said it raised approximately A$912,962 before costs from its fully underwritten pro-rata renounceable entitlement offer, which followed an announcement dated 30 October 2026. The underwriter, Caravel Securities, also advised that firm commitments had been received for a placement of approximately 55 million new fully paid ordinary shares, at A$0.01 per share, to raise a further amount of about A$550,000 before costs.

Each placement share carries one free attaching option for every three shares issued. The attaching Options have the same terms as the entitlement options, including an exercise price of A$0.02 and an expiry date of 3 May 2029.

Sector context

At midday, the ASX Health Care sector was up 3.08%, while Cynata shares moved lower in the session. The announcement is dated 4 November and is not linked to the 5 November price move, so the reason for the day's movement is not set out in the company's release.

What to watch ahead

Investors will follow the settlement of the placement, the issue of the attaching options and the company's next clinical or research update, along with any further Capital raising.

Risks

The company's funding depends on capital raisings, and the issue of further shares and options can dilute existing holders. Clinical and research programs carry scientific and regulatory risk, and the shares are very low-priced and can be volatile.

Final Word

Cynata has completed its entitlement offer and secured a placement, with the new options set to be issued alongside. The share price fell during the session, and the company's next development update will show how the funds are being used.